On Friday, Shares of Tiffany & Co. (NYSE:TIF), lost -3.48% to $85.89.
Tiffany & Co., has declared a regular quarterly dividend of $0.40 per share of Common Stock. The dividend will be paid on October 13, 2015 to stockholders of record on September 21, 2015. Future dividends are subject to declaration by the directors.
Tiffany & Co., through its auxiliaries, designs, manufactures, and retails jewelry worldwide. Its jewelry products comprise fine and solitaire jewelry; engagement rings and wedding bands to brides and grooms; and non-gemstone, sterling silver, gold, and metal jewelry.
Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP), inclined 5.82% to $ 12.72, during its last trading session.
Raptor Pharmaceutical Corp., declared that it has signed a definitive agreement with Tripex Pharmaceuticals to acquire Quinsair, the first inhaled fluoroquinolone approved for the administration of chronic pulmonary infections due to Pseudomonas aeruginosa in adults with cystic fibrosis, expanding its portfolio of rare disease therapies.
Quinsair received marketing authorization by the European Commission and Health Canada in March 2015 and June 2015, respectively. Quinsair, a twice-a-day treatment, contains levofloxacin, a proven antimicrobial active against a wide range of gram negative and gram positive bacteria. Raptor plans to launch Quinsair in Europe and Canada in the first half of 2016, and to talk about the path to potential approval in the same indication in the U.S with the FDA in 2016.
In addition to cystic fibrosis, Quinsair has development potential in two additional orphan diseases with noteworthy unmet need, bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections, for which there are presently few therapeutic options. BE is characterized by abnormal dilatation and destruction of lung bronchi and bronchioles due to chronic recurring infection and long-term inflammation which leads to frequent hospitalizations. NTM are a group of microbes that cause severe and recurrent lung infections, often in individuals who are immune-compromised or who have structural lung disease, such as bronchiectasis. Raptor is evaluating Quinsair’s potential in these therapeutic indications and intends to initiate clinical programs in 2016 in at least one of the indications.
Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The company offers PROCYSBI, a delayed-release capsule, which is used for the administration of nephropathic cystinosis in adults, in addition to in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland.
At the end of Friday’s trade, Shares of Illinois Tool Works Inc. (NYSE:ITW), lost -2.48% to $85.24.
Illinois Tool Works Inc., declared a dividend on the company’s common stock of $0.55 per share for the third quarter of 2015, a 13.4 percent enhance over the quarterly dividend paid in 2014. The dividend equates to $2.20 per share on a full-year basis. The dividend will be paid on October 6, 2015 to shareholders of record as of September 30, 2015.
ITW is a Fortune 200 global diversified industrial manufacturer of value added consumables and specialty equipment with related service businesses. The Company focuses on solid growth, improving profitability and strong returns across its worldwide platforms and divisions. These divisions serve customers and markets around the globe, with a noteworthypresence in developed in addition to emerging markets. ITW’s revenues totaled $14.5 billion in 2014.
Illinois Tool Works Inc. manufactures and sells industrial products and equipment worldwide. It operates through seven segments: Automotive OEM; Test & Measurement and Electronics; Food Equipment; Polymers & Fluids; Welding; Construction Products; and Specialty Products.
Finally, Alamos Gold, Inc. (NYSE:AGI), ended its last trade with -3.32% loss, and closed at $4.37.
Alamos Gold Inc., stated financial results for the quarter ended June 30, 2015 and reviewed its operating, exploration and development activities.
Subsequent to the end of the second quarter, on July 2, 2015, Alamos Gold Inc. and AuRico Gold Inc. accomplished the formerly declared agreement to merge the two companies. Accordingly, the financial statements and associated Administration’s discussion and Analysis of both AuRico and Former Alamos for the three and six-month periods ended June 30, 2015 have been stated separately. For the purposes of this press release, the merged company, which retained the Alamos name, has comprised of the operating and financial results of both Former Alamos and AuRico. The first, second, third and fourth quarters of the Company’s fiscal year are referred to as “Q1″, “Q2″, “Q3″ and “Q4″, respectively.
Alamos Gold, Inc. operates as an intermediate gold producer primarily in North America. The company primarily holds a 100% interest in the Young-Davidson gold mine, which comprises mineral leases and claims totaling 11,000 acres in Northern Ontario, Canada.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
